Frederique Lang
Publications and Insights
- Publication: Taking STRIDES: The Value of Diagnostics Against AMR
- Insight: Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
- Publication: Altering the Trajectory of HIV in Europe
- Publication: Challenges and Solutions for Budget Impact Analysis of Gene Therapies
- Insight: R&D for new drugs to tackle AMR is a high-return investment for all EU member states
- Insight: Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
- Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
- Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
- Publication: Capturing the Broader Value of Antibiotics
- Insight: OHE’s AMR consultation response
- Publication: Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
- Publication: Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
- Bulletin: Unlocking prevention for a healthier society
- Publication: Reimagining Prevention for a Healthier, More Prosperous Society
- Publication: Are Recommendations for HTA of Gene Therapies Being Achieved?
- Insight: New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
- Publication: Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
- Publication: The Lower Drug Costs Now Act and Pharmaceutical Innovation
- Publication: Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
- Publication: Exploring the Financial Sustainability of Gene Therapies
- New: Opportunities to Increase Efficiency in Healthcare
- Publication: Opportunities to Increase Efficiency in Healthcare
- Publication: HTA and Payment Mechanisms for New Drugs to Tackle AMR
- Publication: Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
- Publication: Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
- Publication: Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
- Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
- Publication: How can HTA meet the needs of health system and government decision makers?
- Publication: Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
- Publication: Transferability of HTA
- Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
- Publication: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
- Publication: Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
- Publication: Four Case Studies to Explore the Added Value of Oxford AHSN
- Publication: “New Age” Decision Making in HTA: Is It Applicable in Asia?
- Publication: A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
- Publication: Dementia: The R&D Landscape
- Publication: Exploring the Interdependencies of Research Funders in the UK